Clinical Trials on Hepatitis, Viral, Human in Austria

Total 1093 results

ViiV Healthcare

Completed

Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)

HIV Infections

United States
ViiV Healthcare

Completed

A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants

HIV Infections

United States
Roxane Laboratories

Completed

Bioequivalency Study of Zidovudine Under Fed Conditions

HIV Infections

United States
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Open Label Safety And Efficacy Study Of Pregabalin In Subjects With Nerve Pain Asociated With Human Immunodeficiency Virus (HIV) Neuropathy

HIV Infections | Peripheral Neuropathy

United States, Puerto Rico
407 Doctors
Bristol-Myers Squibb; Merck Sharp & Dohme LLC

Unknown

Once Daily 3TC, Efavirenz and ddI for HIV Infection

HIV Infection | AIDS

Australia
University of Modena and Reggio Emilia

Completed

Aging With HIV at Younger vs Older Age: a Diverse Population With Distinct Comorbidity Profiles (Aging_in_HIV)

HIV Infection | Aging

Australia, Italy, Spain
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of Age

Influenza

United States, Canada
Ology Bioservices

Completed

Phase 3 Study of a H5N1 Vaccine in Adults, Elderly and Specified Risk Groups

Influenza

Austria, Belgium, Finland, Germany, Latvia, Lithuania, Netherlands
Kirby Institute
Medical Research Future Fund; Seqirus Pty Ltd, Australia

Recruiting

Immunosuppression and COVID-19 Boosters

COVID-19

Australia
Merck Sharp & Dohme LLC

Terminated

A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)

Coronavirus Disease (COVID-19)

United States, Austria, Belgium
Valentina Puentmann
Bayer; Alcedis GmbH

Recruiting

Myocardial Protection in Patients With Post-acute Inflammatory Cardiac Involvement Due to COVID-19 (MYOFLAME-19)

Microvascular Angina | Left Ventricular Dysfunction | Vascular Inflammation | Exercise Intolerance | Remodeling, Left Ventricle | Remodeling, Vascular | COVID-19 Associated Cardiac Involvement

Germany, Austria
ViiV Healthcare
Pfizer

Completed

Prospective Observational Epidemiologic Study of Maraviroc's Safety (POEM)

Human Immunodeficiency Virus

United States, Canada, Spain, Belgium, France, United Kingdom, Italy, Brazil, Puerto Rico, Germany, Greece
Novavax

Withdrawn

Evaluation of the Safety and Immunogenicity of SII Vaccine Constructs Based on the SARS-CoV-2 (COVID-19) Variant in Adults

Covid19

Australia
Novartis Vaccines

Completed

Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age

Fever | Influenza

United States, Australia, New Zealand, Philippines, Thailand
Seqirus

Completed

A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatric Population in the USA

Influenza

United States
Australian and New Zealand Intensive Care Research...
The Alfred

Completed

The REDEEM Pilot Study: A Feasibility RCT of Early ECMO in Severe Acute Respiratory Infection, Including COVID-19, WHO (REDEEM)

Covid19 | Mechanical Ventilation Complication | Severe Acute Respiratory Infection

Australia, Germany
Sanofi

Completed

A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX

Japanese Encephalitis

Australia, United States
Medicago

Completed

Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older

Influenza

United States
Seqirus

Completed

A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years

Influenza, Human

United States
BioCryst Pharmaceuticals

Completed

A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza

Acute, Uncomplicated Human Influenza

United States, Australia, New Zealand, South Africa
Kirby Institute
Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme LLC; Gilead Sciences; Hoffmann-La... and other collaborators

Terminated

Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy

HIV Infections | HIV-Associated Lipodystrophy

Australia
Seqirus

Completed

A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults in the USA

Influenza

United States
Kirby Institute
The Alfred; Peter MacCallum Cancer Centre, Australia; St Vincent's Hospital; Monash... and other collaborators

Active, not recruiting

Age-related Clonal Haematopoiesis in an HIV Evaluation Cohort (ARCHIVE) (ARCHIVE)

HIV Infections | Aging

Australia
ModernaTX, Inc.

Active, not recruiting

A Study of Modified mRNA Vaccines in Healthy Adults

Cytomegalovirus | SARS-CoV-2 | Seasonal Influenza | Respiratory Syncytial Virus

United States
Valneva Austria GmbH

Completed

Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries

Encephalitis

United States, Australia, Denmark, Germany, Sweden
Novavax

Completed

Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines

COVID-19

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older

Influenza Immunization

Australia, United States, Puerto Rico
ACM Biolabs

Completed

Booster Dose Study to Assess the Safety and Immunogenicity of ACM-001 Administered Intramuscularly or Intranasally.

SARS-CoV-2 Infection

Australia
Dynavax Technologies Corporation

Completed

Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers

Herpes Zoster | Vaccine-Preventable Diseases | Shingles

Australia
Hoffmann-La Roche

Withdrawn

ESP Study: A Study to Assess the Effect of Adding Fuzeon (Enfuvirtide) to an Antiretroviral Regimen in Fuzeon-Naive Patients With Sustained HIV Viral Suppression.

HIV Infections

Australia
Arcturus Therapeutics, Inc.
Novotech (Australia) Pty Limited; Seqirus

Active, not recruiting

Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults

COVID-19

Australia, Costa Rica, Honduras, Philippines
Boehringer Ingelheim

Completed

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

HIV Infections

Romania, Poland, Austria
GlaxoSmithKline

Completed

Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years

Influenza

United States, Canada
GlaxoSmithKline

Completed

Safety and Efficacy of H1N1 Vaccines in Children Aged 6 Months to Less Than 10 Years of Age

Influenza

Thailand, Australia, Mexico, Costa Rica, Philippines, Colombia, Singapore, Brazil
ModernaTX, Inc.

Completed

A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old

Influenza | SARS-CoV-2

United States
Pfizer

Completed

A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza

Influenza, Human

United States
Seqirus

Completed

A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine

Influenza

United States
ViiV Healthcare

Completed

First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy Participants

HIV Infections

United States
ViiV Healthcare

Recruiting

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy Adults

HIV Infections

United States
Genocea Biosciences, Inc.

Completed

Evaluating New Formulation of Therapeutic HSV-2 Vaccine

Genital Herpes Simplex Type 2

United States
Abbott Biologicals
Quintiles, Inc.

Completed

Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Adults Aged >= 18 and <= 64, Plus Revaccination

Influenza

United States
GlaxoSmithKline

Active, not recruiting

A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults

COVID-19

United States
Medical University of Graz
Medical University of Vienna; University Hospital, Essen; Goethe University; Guy... and other collaborators

Recruiting

The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients (VITDALIZE)

Critical Illness | Covid19 | Vitamin D Deficiency

Austria, Belgium
Apeiron Biologics

Completed

Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19 (APN01-COVID-19)

COVID-19

Denmark, Germany, Austria, Russian Federation, United Kingdom
GlaxoSmithKline

Recruiting

A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults

Influenza, Human

United States
Quidel Corporation

Completed

"Quidel Reader Influenza A + B Test 510(k) and CLIA Waiver Field Study"

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia

Dengue Fever | Dengue Hemorrhagic Fever

Australia
Novartis Vaccines

Completed

Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of Age

Influenza Disease

Argentina, Australia, Chile, Philippines, South Africa
Kirby Institute
Merck Sharp & Dohme LLC

Completed

The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection (PINT)

HIV Infection

Australia
Allergan

Completed

A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease

Dry Eye Disease

France, Spain, Russian Federation, Belgium, Germany, Italy, United Kingdom, Australia

3

Subscribe